Shop By
Catalog No.
Product Name
Application
Product Information
Citations
-
Thrombin Inhibitor
(2R)-Atecegatran is a selective thrombin inhibitor that demonstrates significant anticoagulant activity. This compound is employed in research concerning thromboembolic disorders, aiding in the understanding of coagulation pathways and potential therapeutic strategies. Its effectiveness in modulating thrombin activity makes it a valuable tool in the development of anticoagulant therapies. -
Thrombin Inhibitor
S-18326 is an orally active direct thrombin inhibitor that functions by reversibly binding to the active site of thrombin, thereby preventing the conversion of fibrinogen to fibrin and inhibiting thrombus formation. This compound effectively prolongs clotting times in human plasma and has shown antithrombotic efficacy in various animal models while maintaining normal platelet levels. S-18326 is suitable for research applications related to thromboembolic diseases. -
Thrombin/Factor Xa Inhibitor
SAR107375 is a potent dual inhibitor of thrombin and factor Xa, exhibiting Ki values of 1 nM for factor Xa and 8 nM for thrombin. This compound demonstrates significant anticoagulant activity, making it a valuable tool for research applications focused on thrombosis and coagulation disorders. SAR107375 can be utilized in the study of cardiovascular diseases and the development of novel anticoagulant therapies. -
Thrombin Inhibitor
Thrombin Inhibitor 6 is a highly potent anticoagulant that functions by specifically inhibiting thrombin with an IC50 of 1 nM. This compound is valuable for research applications in anticoagulant therapy and thrombotic disease studies, enabling the exploration of thrombin's role in hemostasis and thrombosis. -
Thrombin Inhibitor
SSR182289 is a selective and potent inhibitor of thrombin, demonstrating competitive inhibition with a Ki of 0.031 µM. This compound exhibits significant anticoagulant activity, achieving an EC100 of 96 nM in thrombin time assays, and effectively inhibits tissue factor-induced thrombin generation with an IC50 of 0.15 µM in human plasma. Additionally, SSR182289 inhibits thrombin-induced aggregation of human platelets with an IC50 of 32 nM, while showing no effect on aggregation induced by other agonists. Such properties make SSR182289 valuable for research into anticoagulation and thrombotic disorders. -
Thrombin Inhibitor
Napsagatran is a potent inhibitor of thrombin, a key enzyme in the coagulation cascade. It demonstrates significant anticoagulant effects both in vitro and in vivo, making it a valuable tool for studying thrombus formation and related cardiovascular functions. This compound is suitable for antithrombotic research applications, contributing to the understanding of thrombotic disorders and potential therapeutic interventions. -
Thrombin Inhibitor
Efegatran sulfate is a potent thrombin inhibitor that effectively inhibits platelet aggregation, demonstrating significant anticoagulant and antithrombotic properties. This compound is valuable for research focused on cardiovascular diseases, hemostasis, and thrombosis. Its mechanism of action makes it a crucial tool for studying thrombin-related pathways and potential therapeutic interventions in coagulation disorders. -
Thrombin Inhibitor
(1R,3S)-THCCA-Asn is a selective thrombin inhibitor that effectively demonstrates anticoagulant properties with an IC50 value between 0.07 to 0.14 μM. This compound is valuable in research applications focused on thrombosis, hemostasis, and the development of therapeutic agents targeting thrombin. Its specific inhibition of thrombin makes it a significant tool for investigating antithrombotic mechanisms and potential cardiovascular therapies. -
Thrombin Inhibitor
BMS 180742 is a selective thrombin exosite inhibitor that disrupts thrombin's ability to interact with its substrates. It exhibits significant inhibition of thrombin-mediated processes, making it a valuable tool for investigating coagulation pathways. This compound is particularly useful in research applications focusing on the modulation of hemostasis and thrombin-related disorders. Notably, BMS 180742 does not exhibit inhibition of arterial thrombosis, providing insights into selective targeting in thrombosis research. -
Thrombin Inhibitor
AT-1459 is a selective, orally active direct thrombin inhibitor with a Ki value of 4.9 nM. It demonstrates significant antithrombotic activity in both rat models of venous and arterial thrombosis, making it a valuable tool for studying thrombosis-related diseases. AT-1459 is suitable for research applications focused on blood coagulation and associated pathologies. -
Thrombin Inhibitor
BCH-2763 is a potent and selective thrombin inhibitor, exhibiting a high affinity for thrombin with a Ki value of 0.11 nM. This compound effectively inhibits fibrin formation, platelet aggregation, and the activity of free thrombin. BCH-2763 is suitable for research applications focused on thrombosis and related cardiovascular studies. -
Thrombin Inhibitor
Efegatran dihydrochloride is a potent thrombin inhibitor that effectively prevents platelet aggregation. This compound exhibits significant anticoagulant and antithrombotic properties, making it valuable for studies related to cardiovascular diseases and clotting disorders. Its mechanism of action provides insight into thrombin-related pathways in various biological research applications. -
Thrombin Inhibitor
LY135305 is a selective thrombin inhibitor that impedes thrombin activation. This compound demonstrates significant anti-metastatic properties, reducing spontaneous metastasis and contributing to improved survival rates in animal models. It is utilized in research focused on thrombin-related pathways and cancer metastasis. -
Thrombin Inhibitor
(21S)-Argatroban is a specific thrombin inhibitor known for its anticoagulant properties. By interfering with thrombin activity, it effectively prolongs blood clotting time, while also reducing platelet adhesion and aggregation. This compound is useful in research applications aimed at understanding coagulation disorders and developing therapeutic strategies for thrombotic diseases. -
Thrombin Inhibitor
Ro 09-1679 is a potent thrombin inhibitor with an IC50 of 33.6 μM, demonstrating significant inhibition of thrombin activity. Additionally, it effectively inhibits factor Xa, trypsin, and papain, with IC50 values of 3.3 μM, 0.04 μM, and 0.0346 μM, respectively. This compound is valuable for research applications focused on coagulation pathways, providing insights into thrombin's role in hemostasis and potential therapeutic interventions. -
Thrombin Inhibitor
NAPAP is a selective direct thrombin inhibitor that binds rapidly to thrombin, effectively inhibiting its enzymatic activity. This compound demonstrates significant potential in reducing lipopolysaccharide (LPS)-induced neuroinflammation and expression of coagulation factors in vivo. NAPAP is valuable for research applications focused on coagulation pathways and neuroinflammatory processes. -
Thrombin Inhibitor
LK-732 is a selective thrombin inhibitor that demonstrates significant anti-thrombotic activity. It exhibits dose-dependent inhibition of hypercoagulability, with an IC50 of 1.3 mg/kg. This compound is suitable for use in cardiovascular and cerebrovascular research applications, providing insights into thrombotic disorders and potential therapeutic interventions. -
Thrombin Inhibitor
DuP 714 is a potent oral thrombin inhibitor that effectively inhibits thrombin-induced platelet aggregation with an IC50 value of 150 nM. This compound is valuable for research into arterial thrombosis, allowing for the investigation of thrombin's role in platelet activation and clot formation. Its selective mechanism makes it a crucial tool for studies aimed at understanding cardiovascular diseases and developing therapeutic strategies. -
Thrombin Inhibitor
LY 806303 is a selective inhibitor of human α-thrombin, functioning primarily through the acylation of Ser-205 within the enzyme's catalytic triad. This modification disrupts the enzymatic activity of thrombin, delineating its role in various coagulation processes. LY 806303 is valuable for research applications focused on thrombin's involvement in hemostasis and thrombosis, providing insights into therapeutic strategies for related diseases. -
α-thrombin Inhibitor
RWJ-671818 is a potent oral inhibitor of human α-thrombin, exhibiting a Ki of 1.3 nM. This compound is particularly relevant in the study of venous and arterial thrombosis, providing insights into thrombotic mechanisms and potential therapeutic interventions. Its specificity for α-thrombin makes it a valuable tool in anticoagulant research. -
a-thrombin Inhibitor
BMS-189664 hydrochloride is a potent and selective reversible inhibitor of alpha-thrombin, exhibiting an IC50 value of 0.046 μM. This compound demonstrates significant anti-thrombotic activity and is suitable for research applications related to arterial and venous thrombosis. Its oral bioavailability makes it a valuable tool for in vivo studies of thrombotic disorders. -
a-thrombin Inhibitor
BMS-189664 is a selective and reversible inhibitor of α-thrombin, exhibiting a potent IC50 of 0.046 μM. This compound is valuable for investigating mechanisms involved in arterial and venous thrombosis. Its orally active nature facilitates its use in preclinical studies aimed at understanding thrombotic disorders and potential therapeutic interventions. -
Thrombin Inhibitor
Napsagatran hydrate is a potent thrombin inhibitor that effectively antagonizes thrombin activity. It demonstrates significant anticoagulant effects both in vitro and in vivo, making it a valuable reagent for antithrombotic research. This compound is suitable for studies focused on coagulation and related pathways, contributing to the development of therapeutics for thrombotic disorders. -
Thrombin Inhibitor
Atecegatran is an orally active competitive thrombin inhibitor targeting thrombin with a Ki value of 2-4 nM. By blocking thrombin's interaction with fibrin and thrombomodulin, it effectively inhibits platelet activation and aggregation. Demonstrating significant anticoagulant properties, Atecegatran exhibits an IC50 range of 93 to 220 nM in various plasma coagulation assays. This reagent is valuable for research focused on thromboembolic disorders and related cardiovascular studies. -
Thrombin Inhibitor
Flovagatran sodium is a potent and reversible thrombin inhibitor with a Ki of 9 nM. This compound demonstrates significant efficacy in studies related to arterial and venous thrombosis, making it a valuable tool for hematological research. Its ability to selectively target thrombin enhances its utility in elucidating mechanisms of coagulation and developing therapeutic strategies for thrombotic disorders. -
Thrombin synthetase Inhibitor
Pirmagrel is a thrombin synthetase inhibitor that effectively reduces thrombin secretion stimulated by lipopolysaccharide. Its primary mechanism involves the inhibition of thrombin synthesis, making it a valuable tool for studies related to coagulation and inflammation. This reagent is applicable in research focusing on thrombotic disorders and assessing the biological pathways influenced by thrombin regulation. -
Thrombin Inhibitor
LB30057 (CI-1028) is a selective thrombin inhibitor with an inhibitory concentration (IC50) of 0.38 nM for human thrombin. This orally active compound is suitable for research on thrombus formation and related cardiovascular studies, making it a valuable tool for investigations into coagulation disorders and antithrombotic therapies. -
Thrombin Inhibitor
Thrombin inhibitor 1 is a potent thrombin inhibitor with a Ki value of 0.66 nM and a 2xaPTT of 0.43 μM. This compound effectively inhibits thrombin activity, making it a valuable tool for studying blood coagulation and developing anticoagulant therapies. Its high specificity and efficacy render it suitable for various research applications in cardiovascular and hemostasis studies. -
Tyrosinase Inhibitor
(E)-2-Methoxycinnamaldehyde is a potent inhibitor of tyrosinase, demonstrating an IC50 of 0.42 mM for mushroom tyrosinase. Isolated from the twigs of Cinnamomum cassia, this compound is relevant in the study of melanin biosynthesis as well as potential applications in skin depigmentation. Additionally, (E)-2-Methoxycinnamaldehyde has been investigated for its role in Parkinson's disease research, providing insights into neuroprotective strategies. -
Tyrosinase Inhibitor
Isobutylamido thiazolyl resorcinol is a selective inhibitor of human tyrosinase with an IC50 of 1.1 μM, demonstrating notable efficacy against melanin production. This compound also shows an IC50 of 108 μM against mushroom tyrosinase, highlighting its specificity. Isobutylamido thiazolyl resorcinol effectively mitigates pigmentation induced by UVB exposure and significantly reduces the visibility of hyperpigmentation related to acne. Its applications in dermatological research make it a valuable tool for studying skin pigmentation processes and developing treatments for skin discoloration disorders. -
Tyrosinase Inhibitor
3',4'-Dihydroxyacetophenone is a potent tyrosinase inhibitor, demonstrating a strong inhibitory effect on enzyme activity with an IC50 value of 10 μM. Isolated from Picea schrenkiana needles, this compound also exhibits antioxidant properties and vasoactive effects, making it valuable for research applications in skin pigmentation and melanogenesis. Its ability to modulate tyrosinase activity positions it as a useful tool in studies related to pigmentation disorders and cosmetic formulations. -
Tyrosinase Inhibitor
(R)-Trolox is a vitamin E analogue and a competitive inhibitor of tyrosinase, exhibiting a Ki value of 0.83 mM and an ID50 of 1.88 mM. This compound demonstrates a greater affinity for tyrosinase compared to its (S) enantiomer, which has a Ki value of 0.61 mM. (R)-Trolox is valuable for research focused on skin pigmentation, oxidative stress, and potential therapeutic applications in disorders related to hyperpigmentation. -
Tyrosinase Inhibitor
Mulberroside F acts as a potent tyrosinase inhibitor, primarily derived from the mulberry plant (Morus alba L.). This compound effectively inhibits tyrosinase activity, leading to a reduction in melanin formation, making it valuable in research related to hyperpigmentation and skin disorders. Additionally, Mulberroside F demonstrates superoxide scavenging activity, contributing to its protective effects against oxidative stress. -
Tyrosinase Inhibitor
4-Bromobenzoic acid is a potent inhibitor of tyrosinase, with an IC50 range of 0-0.3 mg/mL. This compound plays a significant role in the study of melanin biosynthesis and is applicable in research focused on cosmetic whitening and pigmentation disorders. Its metabolism via the protocatechuic acid (PCA) pathway provides additional insights into its biochemical interactions and potential therapeutic benefits. -
Tyrosinase Inhibitor
Oxyresveratrol 2-O-β-D-glucopyranoside is a phenolic compound that acts as an effective inhibitor of the enzyme tyrosinase, exhibiting an IC50 of 29.75 μM. This compound plays a significant role in regulating melanin production and is of interest in research applications related to skin pigmentation disorders and cosmetic formulations. Its inhibitory effect on tyrosinase makes it a valuable reagent for studies exploring pigmentary conditions and related therapeutic interventions. -
Tyrosinase Inhibitor
5-Feruloylquinic acid is a potent inhibitor of tyrosinase, an enzyme involved in melanin biosynthesis. Isolated from green coffee beans, this hydroxycinnamic acid derivative exhibits significant antioxidant properties and has demonstrated anticancer activity against various cancer types, including lymphoma, oral epidermal cancer, and breast cancer. Its ability to modulate enzymatic activity and protect against oxidative stress makes it a valuable compound for research in cancer biology and metabolic studies. -
Tyrosinase Inhibitor
Mirificin, a tyrosinase inhibitor derived from Puerariae Lobatae Radix, demonstrates inhibitory activity with an IC50 of 12.66 μM. This isoflavone is of particular interest in studies related to pigmentation disorders and skin hyperpigmentation, offering a potential therapeutic avenue for regulating melanin synthesis. Its ability to modulate tyrosinase activity underscores its relevance in chemical and pharmacological research applications. -
Tyrosinase Inhibitor
2-Methoxycinnamic acid is a noncompetitive inhibitor of tyrosinase, an enzyme critical in melanin biosynthesis. This compound effectively reduces melanin production, making it valuable in studies focused on pigmentation disorders and skin whitening applications. Its ability to modulate tyrosinase activity positions it as a significant reagent for research in dermatology and cosmetic science. -
Tyrosinase Iinhibitor
Dihydromorin is a natural flavanonol compound that acts as a potent inhibitor of tyrosinase. Its inhibitory activity on this enzyme is significant for research applications focused on regulating melanin production, offering potential insights into hyperpigmentation disorders and skin-related studies. Dihydromorin can serve as an important tool for investigating mechanisms of skin pigmentation and the effects of natural compounds on melanin synthesis. -
Tyrosinase Inhibitor
Oxyresveratrol 3'-O-β-D-glucopyranoside is a phenolic compound that serves as an effective inhibitor of tyrosinase, with an IC50 value of 1.64 μM. This compound is derived from Morus nigra root and exhibits significant potential for applications in studies related to pigmentation and skin disorders. Its inhibitory action on tyrosinase makes it a valuable tool for research in cosmetic and dermatological fields. -
Tyrosinase Inhibitor
Neorauflavane is a potent inhibitor of tyrosinase, exhibiting an IC50 of 30 nM for monophenolase activity and 500 nM for diphenolase activity. Derived from Campylotropis hirtella, this compound effectively reduces melanin content in B16 melanoma cells. Neorauflavane serves as a valuable tool for research in pigmentation disorders and skin biology. -
Tyrosinase Inhibitor
Tyrosinase-IN-11 is a potent inhibitor of tyrosinase, exhibiting IC50 values of 50 nM for L-tyrosinase and 64 nM for L-dopa. This compound demonstrates significant antioxidant properties and low cytotoxicity, making it suitable for biological assays. Tyrosinase-IN-11 is particularly relevant for research into skin hyperpigmentation and related dermatological applications. -
Mushroom Tyrosinase Inhibitor
Sanggenon O is a potent inhibitor of mushroom tyrosinase, demonstrating an IC50 value of 1.15 μM. This compound, derived from Morus nigra, is valuable for research applications focused on enzymatic activity modulation, particularly in studies related to melanin biosynthesis and skin pigmentation. Its inhibitory effects on tyrosinase make it a useful tool in cosmetic and therapeutic research aimed at addressing hyperpigmentation and related conditions. -
Tyrosinase Inhibitor
Obtusifolin-2-O-glucoside is a potent inhibitor of tyrosinase, demonstrating an IC50 value of 9.2 μM. This compound, which can be isolated from cassia seed, has significant implications in the study of melanogenesis and skin pigmentation. Its inhibitory properties make it a valuable tool for research into hyperpigmentation disorders and skin-lightening agents. -
Tyrosinase Inhibitor
Viscumneoside III is a dihydroflavone O-glycoside that functions as a potent inhibitor of tyrosinase, exhibiting an IC50 value of 0.5 mM. This compound demonstrates significant anti-angina pectoris activity, making it a valuable reagent for research into melanogenesis and cardiovascular health. Its ability to modulate tyrosinase activity further supports its applications in studies related to pigmentation disorders and metabolic conditions. -
Tyrosinase Inhibitor
Isolindleyin is a butyrophenone that acts as a potent inhibitor of tyrosinase, exhibiting a Kd of 54.8 μM in human tyrosinase assays. This compound demonstrates notable anti-inflammatory, analgesic, and anti-melanogenic activities, making it valuable for research in skin-related disorders and the modulation of pigmentation processes. Its multifunctional properties position it as a significant tool for studying enzyme inhibition and related biological pathways. -
Tyrosinase Inhibitor
Chimonanthine is an alkaloid derived from Chimonanthus praecox, known for its ability to inhibit tyrosinase activity. This compound also reduces the expression of tyrosine-related protein-1 mRNA, leading to the suppression of melanogenesis. Due to its mechanism of action, Chimonanthine is valuable in research focused on pigmentation disorders and potential therapeutic applications in hyperpigmentation conditions. -
Tyrosinase Inhibitor
Kojic acid dipalmitate is a derivative of kojic acid and functions as a reversible competitive inhibitor of tyrosinase. This compound is primarily studied for its skin-lightening properties due to its ability to inhibit melanin production. It is frequently utilized in research applications aiming to understand pigmentation mechanisms and the development of cosmetic agents targeting hyperpigmentation disorders. -
Tyrosinase Inhibitor
6-Hydroxykaempferol is a competitive inhibitor of tyrosinase, exhibiting an IC50 value of 124 μM. This flavonoid demonstrates a Ki value of 148 μM when L-DOPA serves as the substrate, effectively inhibiting the enzymatic activity by binding to the active site. Its inhibitory properties make it a valuable tool for research in skin pigmentation, cosmetic formulations, and enzymatic activity studies related to melanogenesis. -
Tyrosinase Inhibitor
Tyrosinase-IN-16 is a potent inhibitor of tyrosinase, exhibiting a Ki value of 470 nM. This compound demonstrates significant cytotoxicity against B16F10 melanoma cells, achieving over 90% inhibition at a concentration of 20 μM. Tyrosinase-IN-16 is valuable for studies investigating mechanisms of melanin synthesis and potential therapeutic applications in pigmentary disorders and melanoma research.
